Training grant in hemostasis and thrombosis

描述（由申请人提供）：宾夕法尼亚大学（UPENN）和费城儿童医院（CHOP）获得了NHLBI赞助的T32培训资助，用于支持过去9年在止血、血栓形成和血管生物学等相互关联领域的博士后和博士生。这些领域具有重要的临床意义，因为心脏病发作和中风仍然是我们工业社会死亡的头号原因。许多其他疾病，从深静脉血栓形成到肝素诱导的血小板减少，甚至镰状细胞病，都具有很强的临床重要性，并涉及止血/血栓功能障碍。然而，尽管有这些迫切的临床需求，潜在的受训者却被吸引到癌症研究或心脏病学等平行领域。我们相信，我们已经开发了一个成功的竞争性项目，部分原因是UPENN/CHOP校园在止血/血栓形成/血管生物学方面的研究人员和机会是高效的，互动的，并致力于指导下一代研究人员。这种丰富的环境，加上我们认为是一个非常精心设计和实施的T32愿景，使我们在过去的9年里吸引了强大的博士后和博士后培训生。在未来5年的支持中，我们建议保留相同数量的学员，但通过以下3个变化进一步加强该计划：1)每周由两名参与培训的教师参加止血和血栓形成的期刊俱乐部，现在将成为强制性的。2)我们所有的学员都需要一个为期一周的强化临床凝血实验室课程，以使我们的博士学员在大型三级医院进行的评估和治疗止血/血栓性疾病患者的临床测试中有一个视觉形象和舒适。3)我们邀请了一名前UPENN教师作为外部审稿人参加，他曾接受过T32主任的培训，现在是制药领域止血疾病临床试验的领导者。他将为我们的学员提供重要的见解和指导，因为他们中的许多人将从专注于基础研究的学术界过渡到更多的私营企业的转化和临床研究。因此，我们相信我们是一个优秀的培训项目，拥有非常丰富和互动的教师团队，他们提供了重要的研究机会，同时还有强大的教学计划和指导，我们将继续培养将对我们的研究领域做出重要贡献的个人。

DESCRIPTION (provided by applicant): The University of Pennsylvania (UPENN) and Children's Hospital of Philadelphia (CHOP) have had an NHLBI- sponsored T32 training grant for the support of pre- and post-doctoral trainees for the past 9 years in the inter- related areas of hemostasis, thrombosis and vascular biology. These areas have great clinical importance as heart attacks and strokes remain the number one cause of mortality in our industrial society. Many other diseases from deep vein thrombosis to heparin-induced thrombocytopenia to even Sickle Cell Disease are of strong clinical importance and involve hemostatic/thrombotic dysfunction. Yet in spite of these pressing clinical needs, potential trainees are drawn instead into the parallel fields of cancer research or cardiology. We believe that we have developed a successful competitive program in part because the research faculty and opportunities on the UPENN/CHOP campus in hemostasis/ thrombosis/vascular biology is highly productive, interactive and committed to mentoring the next generation of investigators. This rich environment, plus what we believe is a very well-designed and implemented T32 vision, has allowed us to attract strong pre- and postdoctoral trainees over the past 9 years. In the coming 5 years of support, we propose to retain the same number of trainees, but further strengthen the program by the following 3 changes: 1) a weekly journal club in hemostasis and thrombosis by two of our participating faculty members that had been informally attended by the trainees will now become mandatory. 2) A one week course intensive clinical coagulation laboratory course will be required of all of our trainees to give even our PhD trainees a visual image and comfort in the clinical tests that are done at a major tertiary hospital in the evaluation and care of patients with hemostatic/thrombotic disorders. 3) We have invited a former UPENN faculty member, who had trained with the T32's Director and is now a leader in clinical trials in hemostatic disorders in the pharmaceutical field, to participate as an external reviewer. He will provide important insights and guidance to our trainees as many of them will transition from academia with a focus on basic research to more translational and clinical research in private industry. Thus, we believe that we are an outstanding training program with an extra-ordinarily rich and interactive group of faculty members that has provided important research opportunities along with a concurrent strong didactic program and mentoring and that we will continue to train individuals who will make important contributions to our research field.